HCM

Hutchmed (China) Limited

• TipRanks·32m ago

  Hutchmed’s FRUSICA-2 Kidney Cancer Trial Reaches Completion: What Investors Should Watch

• TipRanks·21h ago

  Analysts Are Bullish on These Healthcare Stocks: Opus Genetics (IRD), HUTCHMED (HCM)

• TipRanks·10/01 16:30

  Hutchmed Advances HMPL-A830 Trial, Keeping Oncology Pipeline – And Investor Interest – Alive

• Seeking Alpha·09/29 17:28

  AstraZeneca submits NDA for savolitinib + Tagrisso for NSCLC

• Benzinga·09/29 08:29

  Reported Earlier, HUTCHMED Announces AstraZeneca Submitted US NDA For ORPATHYS Plus TAGRISSO In MET-Driven EGFR-Mutated NSCLC, Supported By Phase III SAFFRON Trial

• NASDAQ·09/29 03:56

  HUTCHMED Seeks FDA Approval For ORPATHYS-TAGRISSO In Resistant Lung Cancer

• TipRanks·09/29 00:06

  Hutchmed says AstraZeneca submits NDA for ORPATHYS+TAGRISSO in NSCLC

• NASDAQ·09/28 03:07

  HUTCHMED Starts Global Phase 1 Trial Of KRAS-EGFR Therapy HMPL-A830 In Solid Tumors

• TipRanks·09/28 00:45

  Hutchmed initiates Phase Ia part of trial of HMPL-A830

• TipRanks·09/24 16:30

  Hutchmed’s HMPL-760 Trial Completion in Tough Lymphoma Sets Up a Key Pipeline Catalyst

• Seeking Alpha·09/21 09:37

  Chinese biopharma stocks rally as U.S. signals openness to drug licensing

• TipRanks·09/18 16:31

  Hutchmed Completes Food-Effect Study on HMPL-760, Marking a Subtle De-Risking Step for Investors

• Seeking Alpha·09/18 13:22

  5 Undervalued Oncology Stocks Wall Street Is Overlooking

• Benzinga·09/18 07:54

  HUTCHMED (China) Reports H1 2026 Results: Full Earnings Call Transcript

• TipRanks·09/09 00:25

  Citic Securities Remains a Buy on HUTCHMED (China) (HCM)